What is a stock summary page? Click here for an overview.
Business Description
Aarti Drugs Ltd
ISIN : INE767A01016
Share Class Description:
NSE:AARTIDRUGS: Shs DematerialisedCompare
Compare
Traded in other countries / regions
524348.India Index Membership
NIFTY 500 IPO Date
2003-09-19Description
Aarti Drugs Ltd is a pharmaceutical company. It offers active pharmaceutical ingredients (APIs), pharma intermediaries, specialty chemicals, and formulations in a range of therapeutic categories, such as anti-inflammatory, cardioprotectant, antibiotic, antidiabetic, and vitamins among others. The product offerings of the company comprise Aceclofenac, Celecoxib, Moxifloxacin, and others. The firm caters to both domestic and international markets and derives a majority of its revenue from its business in India.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.05 | |||||
| Equity-to-Asset | 0.53 | |||||
| Debt-to-Equity | 0.46 | |||||
| Debt-to-EBITDA | 2 | |||||
| Interest Coverage | 6.63 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 3.22 | |||||
| Beneish M-Score | -2.87 | |||||
| WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 5.7 | |||||
| 3-Year EBITDA Growth Rate | -9.7 | |||||
| 3-Year EPS without NRI Growth Rate | -14.6 | |||||
| 3-Year FCF Growth Rate | 26.3 | |||||
| 3-Year Book Growth Rate | 12.5 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 77.94 | |||||
| 9-Day RSI | 66.61 | |||||
| 14-Day RSI | 58.89 | |||||
| 3-1 Month Momentum % | -13.63 | |||||
| 6-1 Month Momentum % | -26.67 | |||||
| 12-1 Month Momentum % | -28.4 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.61 | |||||
| Quick Ratio | 1.01 | |||||
| Cash Ratio | 0.04 | |||||
| Days Inventory | 96.82 | |||||
| Days Sales Outstanding | 110.09 | |||||
| Days Payable | 82.66 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 0.27 | |||||
| Dividend Payout Ratio | 0.06 | |||||
| 3-Year Dividend Growth Rate | -26.3 | |||||
| Forward Dividend Yield % | 0.27 | |||||
| 5-Year Yield-on-Cost % | 0.75 | |||||
| 3-Year Average Share Buyback Ratio | 0.5 | |||||
| Shareholder Yield % | 0.95 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 19.99 | |||||
| Operating Margin % | 10.29 | |||||
| Net Margin % | 6.61 | |||||
| FCF Margin % | 5.74 | |||||
| ROE % | 12.15 | |||||
| ROA % | 6.35 | |||||
| ROIC % | 9.07 | |||||
| 3-Year ROIIC % | -17.1 | |||||
| ROC (Joel Greenblatt) % | 12.98 | |||||
| ROCE % | 15.03 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 21.96 | |||||
| PE Ratio without NRI | 21.71 | |||||
| Shiller PE Ratio | 19.42 | |||||
| Price-to-Owner-Earnings | 14.66 | |||||
| PEG Ratio | 3.15 | |||||
| PS Ratio | 1.44 | |||||
| PB Ratio | 2.61 | |||||
| Price-to-Tangible-Book | 2.61 | |||||
| Price-to-Free-Cash-Flow | 25.27 | |||||
| Price-to-Operating-Cash-Flow | 9.33 | |||||
| EV-to-EBIT | 16.18 | |||||
| EV-to-EBITDA | 13.19 | |||||
| EV-to-Revenue | 1.68 | |||||
| EV-to-FCF | 28.96 | |||||
| Price-to-GF-Value | 0.83 | |||||
| Price-to-Projected-FCF | 1.89 | |||||
| Price-to-DCF (Earnings Based) | 1.19 | |||||
| Price-to-DCF (FCF Based) | 0.97 | |||||
| Price-to-Median-PS-Value | 1.04 | |||||
| Price-to-Graham-Number | 1.59 | |||||
| Price-to-Net-Current-Asset-Value | 32.04 | |||||
| Earnings Yield (Greenblatt) % | 6.18 | |||||
| FCF Yield % | 3.98 | |||||
| Forward Rate of Return (Yacktman) % | -2.02 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Aarti Drugs Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ₹) | 23,105.508 | ||
| EPS (TTM) (₹) | 16.595 | ||
| Beta | 0.91 | ||
| 3-Year Sharpe Ratio | -0.26 | ||
| 3-Year Sortino Ratio | -0.4 | ||
| Volatility % | 35.18 | ||
| 14-Day RSI | 58.89 | ||
| 14-Day ATR (₹) | 10.979063 | ||
| 20-Day SMA (₹) | 343.495 | ||
| 12-1 Month Momentum % | -28.4 | ||
| 52-Week Range (₹) | 312 - 635 | ||
| Shares Outstanding (Mil) | 91.27 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Aarti Drugs Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Aarti Drugs Ltd Stock Events
| Event | Date | Price (₹) | ||
|---|---|---|---|---|
| No Event Data | ||||
Aarti Drugs Ltd Frequently Asked Questions
What is Aarti Drugs Ltd(NSE:AARTIDRUGS)'s stock price today?
The current price of NSE:AARTIDRUGS is ₹364.60. The 52 week high of NSE:AARTIDRUGS is ₹635.00 and 52 week low is ₹312.00.
When is next earnings date of Aarti Drugs Ltd(NSE:AARTIDRUGS)?
The next earnings date of Aarti Drugs Ltd(NSE:AARTIDRUGS) is 2025-05-02 Est..
Does Aarti Drugs Ltd(NSE:AARTIDRUGS) pay dividends? If so, how much?
The Dividend Yield %  of Aarti Drugs Ltd(NSE:AARTIDRUGS) is 0.27% (As of Today), Highest Dividend Payout Ratio of Aarti Drugs Ltd(NSE:AARTIDRUGS) was 0.24. The lowest was 0.03. And the median was 0.05. The  Forward Dividend Yield % of Aarti Drugs Ltd(NSE:AARTIDRUGS) is 0.27%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers